A citation-based method for searching scientific literature

Areej Abuhammad, Mutasem Taha. Future Med Chem 2016
Times Cited: 11







List of co-cited articles
87 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity








Designing screens: how to make your hits a hit.
W Patrick Walters, Mark Namchuk. Nat Rev Drug Discov 2003
263
72


Discovery of new antifungal leads via pharmacophore modeling and QSAR analysis of fungal N-myristoyl transferase inhibitors followed by in silico screening.
Mutasem O Taha, Amjad M Qandil, Tariq Al-Haraznah, Reema Abu Khalaf, Hiba Zalloum, Amal G Al-Bakri. Chem Biol Drug Des 2011
17
63

Validation studies of the site-directed docking program LibDock.
Shashidhar N Rao, Martha S Head, Amit Kulkarni, Judith M LaLonde. J Chem Inf Model 2007
173
63




Elaborate ligand-based modeling reveal new migration inhibitory factor inhibitors.
Mahmoud A Al-Sha'er, Sonya VanPatten, Yousef Al-Abed, Mutasem O Taha. J Mol Graph Model 2013
16
63

LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites.
C M Venkatachalam, X Jiang, T Oldfield, M Waldman. J Mol Graph Model 2003
605
54





Ligand-based modeling followed by in vitro bioassay yielded new potent glucokinase activators.
Mutasem O Taha, Maha Habash, Ma'mon M Hatmal, Ahmed H Abdelazeem, Amjad Qandil. J Mol Graph Model 2015
16
54


The challenge of selecting protein kinase assays for lead discovery optimization.
Haiching Ma, Sean Deacon, Kurumi Horiuchi. Expert Opin Drug Discov 2008
127
54


Computer-aided discovery of new FGFR-1 inhibitors followed by in vitro validation.
Shada J Alabed, Mohammad Khanfar, Mutasem O Taha. Future Med Chem 2016
12
45



Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening.
Mutasem O Taha, Yasser Bustanji, Amal G Al-Bakri, Al-Motassem Yousef, Waleed A Zalloum, Ihab M Al-Masri, Naji Atallah. J Mol Graph Model 2007
71
36


QSAR studies in the discovery of novel type-II diabetic therapies.
Areej Abuhammad, Mutasem O Taha. Expert Opin Drug Discov 2016
14
36



Molecular properties that influence the oral bioavailability of drug candidates.
Daniel F Veber, Stephen R Johnson, Hung-Yuan Cheng, Brian R Smith, Keith W Ward, Kenneth D Kopple. J Med Chem 2002
36

Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm.
Guosheng Wu, Daniel H Robertson, Charles L Brooks, Michal Vieth. J Comput Chem 2003
876
36



Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors.
Rand Shahin, Saja Alqtaishat, Mutasem O Taha. J Comput Aided Mol Des 2012
27
36


Ligand-based modeling of diverse aryalkylamines yields new potent P-glycoprotein inhibitors.
Dana A AlQudah, Malek A Zihlif, Mutasem O Taha. Eur J Med Chem 2016
16
36



Evaluation of novel Akt1 inhibitors as anticancer agents using virtual co-crystallized pharmacophore generation.
Mahmoud A Al-Sha'er, Iman Mansi, Inas Almazari, Nancy Hakooz. J Mol Graph Model 2015
10
40

Ligand-based computational modelling of platelet-derived growth factor beta receptor leading to new angiogenesis inhibitory leads.
Rua'a A Al-Aqtash, Malek A Zihlif, Hana Hammad, Zeyad D Nassar, Jehad Al Meliti, Mutasem O Taha. Comput Biol Chem 2017
9
44



Virtual screening using protein-ligand docking: avoiding artificial enrichment.
Marcel L Verdonk, Valerio Berdini, Michael J Hartshorn, Wijnand T M Mooij, Christopher W Murray, Richard D Taylor, Paul Watson. J Chem Inf Comput Sci 2004
317
27

Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening.
Mutasem O Taha, Naji Atallah, Amal G Al-Bakri, Catherine Paradis-Bleau, Hiba Zalloum, Khaled S Younis, Roger C Levesque. Bioorg Med Chem 2008
45
27

Ligand-based and structure-based approaches in identifying ideal pharmacophore against c-Jun N-terminal kinase-3.
B V S Suneel Kumar, Rohith Kotla, Revanth Buddiga, Jyoti Roy, Sardar Shamshair Singh, Rambabu Gundla, Muttineni Ravikumar, Jagarlapudi A R P Sarma. J Mol Model 2011
10
30


Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates.
J Kirchmair, S Distinto, D Schuster, G Spitzer, T Langer, G Wolber. Curr Med Chem 2008
53
27

Pharmacophore modelling: applications in drug discovery.
Thierry Langer, Rémy D Hoffmann. Expert Opin Drug Discov 2006
28
27


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.